Novo Nordisk

Foreign Filer Report • Aug 30, 2024

6-K 1 f6k_083024.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____

FORM 6-K

____

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

August 30, 2024

____

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

____

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

Field: Page; Sequence: 1

Field: /Page

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 30 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

| a) | Details of the person discharging managerial responsibilities/person
closely associated — Name of the Board member/Executive/Associated Person | Douglas Langa | |
| --- | --- | --- | --- |
| 2 | Reason
for the notification | | |
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details
of the transaction(s) | | |
| a) | Description
of the financial instrument, | ADRs | |
| | type of instrument, | | |
| | Identification code | NVO | |
| b) | Nature of the transaction | Purchase of ADRs | |
| c) | Price(s) and volume(s) | | |
| | | Price(s) | Volume(s) |
| | | DKK 904.41 | 12.742 ADRs |
| | | DKK 904.35 | 4.047 ADRs |
| d) | Aggregated information | | |
| | · Aggregated volume | 16.789 ADRs | |
| | · Price | DKK 15,183.93 | |
| e) | Date of the transaction | 2024-08-28 | |
| f) | Place of the transaction | New York Stock Exchange | |

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Field: Page; Sequence: 2

Field: /Page

Page 2 of 2

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com	David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
Sina Meyer +45 3079 6656 azey@novonordisk.com	Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com

Novo Nordisk A/S Investor Relations
Company
announcement No 67 / 2024

Field: Page; Sequence: 3

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: August 30, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer

Field: Rule-Page

Field: /Rule-Page